Valerio Therapeutics

C4X

Company Profile

  • Business description

    Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.

  • Contact

    49, Boulevard du General
    Martial Valin
    Paris75015
    FRA

    T: +33 145587600

    https://www.valeriotx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    41

Stocks News & Analysis

stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,720.50116.10-1.31%
CAC 408,080.7466.09-0.81%
DAX 4025,463.81272.43-1.06%
Dow JONES (US)49,097.061,101.11-2.19%
FTSE 10010,452.6898.49-0.93%
HKSE22,841.62453.13-1.95%
NASDAQ23,879.20550.69-2.25%
Nikkei 22558,215.981,228.23-2.07%
NZX 50 Index14,129.92117.33-0.82%
S&P 5007,175.83147.80-2.02%
S&P/ASX 2008,617.30113.10-1.30%
SSE Composite Index3,577.6210.21-0.28%

Market Movers